Mats Jerkeman
101 – 150 of 177
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Emerging role of SOX11 in mantle cell lymphoma
(
- Contribution to journal › Scientific review
-
Mark
Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study
(
- Contribution to journal › Article
-
Mark
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Scientific review
-
Mark
The impact of age on survival of diffuse large B-cell lymphoma - a population-based study
(
- Contribution to journal › Article
-
Mark
Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.
(
- Contribution to journal › Article
-
Mark
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
(
- Contribution to journal › Article
-
Mark
Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009 - trends in cure proportions by clinical characteristics.
(
- Contribution to journal › Article
-
Mark
Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.
(
- Contribution to journal › Article
-
Mark
Central nervous system relapse in peripheral T-cell lymphomas: A Swedish lymphoma registry study.
(
- Contribution to journal › Article
-
Mark
Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study
(
- Contribution to journal › Article
-
Mark
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: A comparison of Nordic MCL2, HOVON-45, and European MCLYounger trials.
2015) In Leukemia(
- Contribution to journal › Article
-
Mark
Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
2015) In European Journal of Haematology(
- Contribution to journal › Article
-
Mark
Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.
2015) In Hematological Oncology(
- Contribution to journal › Article
-
Mark
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.
(
- Contribution to journal › Article
- 2014
-
Mark
Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study
(
- Contribution to journal › Article
-
Mark
High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
(
- Contribution to journal › Letter
-
Mark
Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma.
(
- Contribution to journal › Article
-
Mark
Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry
(
- Contribution to journal › Article
-
Mark
Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays.
(
- Contribution to journal › Article
-
Mark
Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
(
- Contribution to journal › Article
-
Mark
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study.
(
- Contribution to journal › Article
-
Mark
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
(
- Contribution to journal › Article
- 2013
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
(
- Contribution to journal › Article
- 2012
-
Mark
Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Expanded clinical and experimental use of SOX11-using a monoclonal antibody
(
- Contribution to journal › Article
-
Mark
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy
(
- Contribution to journal › Article
-
Mark
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
(
- Contribution to journal › Article
- 2011
-
Mark
Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.
(
- Contribution to journal › Article
-
Mark
Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.
(
- Contribution to journal › Article
-
Mark
Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy
(
- Contribution to journal › Article
-
Mark
Nordic MCL2 Trial of 1St-Line Intensive Immunochemotherapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: Still Encouraging Results After Median 5½ Years Observation Time
2011) Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem In Biology of Blood and Marrow Transplantation 17(2). p.196-196(
- Contribution to journal › Published meeting abstract
-
Mark
Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group.
(
- Contribution to journal › Article
-
Mark
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
(
- Contribution to journal › Article
- 2010
-
Mark
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
(
- Contribution to journal › Article
-
Mark
Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose Dense Chemoimmuno therapy and CNS Prophylaxis Results From a Nordic Lymphoma Group Phase II Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
(
- Contribution to journal › Article
-
Mark
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
(
- Contribution to journal › Article
-
Mark
High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples.
(
- Contribution to journal › Article
-
Mark
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
(
- Contribution to journal › Article
-
Mark
SOX11 expression correlates to promoter methylatuion and regulates tumor growth in hematopoietic malignancies
(
- Contribution to journal › Article
- 2009
-
Mark
Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA
2009) 45th Annual Meeting of the American-Society-of-Clinical-Oncology In Journal of Clinical Oncology 27(15).(
- Contribution to journal › Published meeting abstract
-
Mark
Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas
(
- Contribution to journal › Article
-
Mark
(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)
(
- Contribution to journal › Published meeting abstract
-
Mark
Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells.
(
- Contribution to journal › Article
-
Mark
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
(
- Contribution to journal › Article
-
Mark
Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma.
(
- Contribution to journal › Article
- 2008
-
Mark
Transformed diffuse large B cell lymphomas differ from follicular lymphomas in both gene and protein expression
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.111-111(
- Contribution to journal › Published meeting abstract